- ticket title
- Egypt’s Parliament Moves to Extend Presidential Term Limits
- FACT CHECK: Declaring Emergency for Wall Not So Ordinary
- US Military Denies Taking Part in Raid on Al-Qaida Site in Libya
- Desk Review of Shelter and NFI Studies in Libya (December 2018)
- Supreme Commander of Libyan Army appoints Chief of General Staff
BETHESDA, Maryland, May 31, 2018 /PRNewswire/ — Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 3, at 4:15 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, Chief Technical Officer of NW Bio, will discuss the interim data that was published on May 29 from the Company’s Phase 3 trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer.
In addition, if time permits, certain physicians and long-term survivor patients may describe their personal experiences with DCVax-L.
Arrangements are being made for Dr. Bosch’s presentation to be webcast. Details will be posted on the Company’s website (www.nwbio.com) under the heading “Most Recent Presentations” when the arrangements are completed. It is anticipated that the webcast will be available for review after the presentation on the Company’s website. This presentation is not an official presentation of the 2018 ASCO Annual Meeting. It is not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation. Not CME-accredited.
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both North America and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company’s lead program is a 331-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal form of brain cancer, and is an “orphan disease.” The Company is also pursuing a Phase I/II trial with DCVax-Direct for all types of inoperable solid tumor cancers. It has completed the 40-patient Phase I portion of the trial, and is preparing for the Phase II portion. The Company previously conducted a Phase I/II trial with DCVax-L for metastatic ovarian cancer together with the University of Pennsylvania.
Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” “design,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as risks related to the Company’s ability to complete its clinical trials on a timely basis, uncertainties about the clinical trials process, uncertainties about the timely performance of third parties, risks related to whether the Company’s products will demonstrate safety and efficacy, risks related to the Company’s ongoing ability to raise additional capital, and other risks included in the Company’s Securities and Exchange Commission (“SEC”) filings. Additional information on the foregoing risk factors and other factors, including Risk Factors, which could affect the Company’s results, is included in its SEC filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.